Pharmaceutical Policy and Pricing: Are Other Countries Getting Greater Value?
Spending on prescription drugs in the U.S. rose at a faster clip in 2009 than spending for hospital and physician care, a trend that is expected to continue through 2020. The desire to get a handle on drug spending is a focus not only in the U.S. but in other countries as well. What are some strategies used in our country and in the UK, Germany and France to control pharmaceutical spending? How well are these strategies working? To address these and related questions, the Alliance for Health Reform and The Commonwealth Fund sponsored this briefing.
For more information and access to the presentation slides, please visit the Alliance’s event page.
The panel was co-moderated by Ed Howard of the Alliance for Health Reform and Robin Osborn of The Commonwealth Fund.
Sir Andrew Dillon, National Institute for Health and Clinical Excellence (England)
Rainer Hess, Gemeinsamer Bundesausschuss/Federal Joint Committee (Germany)
Jean-Luc Harousseau, M.D., Authorite de Sante (HAS)/National Authority for Health (France)
Ian Spatz, Manatt, Phelps & Phillips, LLP and Manatt Health Solutions (United States)
also of interest
- Financing the Response to AIDS in Low- and Middle-Income Countries: International Assistance from Donor Governments in 2012
- Snapshots: Premiums, Cost-Sharing and Coverage at Public, Private and Non-Profit Firms
- Snapshots: The Prevalence and Cost of Deductibles in Employer Sponsored Insurance
- Health Care Costs: A Primer